Inhibitory Effect of a Selective Thromboxane A2 Receptor Antagonist, EP 092, on Platelet Aggregation in Whole Blood Ex Vivo and in Vivo

Overview

Journal Br J Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 1989 Feb 1

PMID 2522336

Citations 1

Authors

R F Booth

A C Honey

N Lad

D P Tuffin

P J Wade

Affiliations

Soon will be listed here.

Abstract

1. The inhibitory effect of a selective prostaglandin H2 (PGH2)/thromboxane A2 receptor antagonist, EP 092, on platelet aggregatory responses in whole blood ex vivo (guinea-pig: Rhesus monkey) and intravascular aggregation in vivo (rabbit) has been investigated. 2. Collagen (0.1-10.0 micrograms ml-1) caused a concentration-dependent decrease in single platelet count in samples of both guinea-pig and Rhesus monkey citrated whole blood incubated ex vivo. EP 092 administered to guinea-pigs by intravenous (0.1-3.0 mg kg-1) or oral (1.0-10.0 mg kg-1) routes significantly inhibited the platelet responses to collagen (ED50 values 1.3 +/- 0.2 and 1.4 +/- 0.2 mg kg-1 respectively). Similar potency against collagen-induced whole blood aggregation was observed in Rhesus monkey blood samples following EP 092 given orally (ED50 0.9 +/- 0.3 mg kg-1). 3. The duration of action of EP 092 against collagen aggregatory responses ex vivo in both guinea-pigs and Rhesus monkeys was between 3 and 6 h following oral administration at 3.0 mg kg-1. 4. The inhibitory activity demonstrated by EP 092 against collagen-induced aggregation of Rhesus monkey whole blood ex vivo was not accompanied by any significant reduction in thromboxane A2 formation except at the highest dose tested (10 mg kg-1). 5. The intravascular aggregatory response induced by collagen or thrombin in the anaesthetized rabbit was significantly inhibited by an intravenous infusion of EP 092 (10 mg kg-1). EP 092 appeared less potent and its effect was of shorter duration in this preparation compared with its inhibitory effect on ex vivo aggregation, being evident immediately after infusion of drug but not after a further 30 min. 6. It is concluded that collagen-induced platelet aggregatory response in guinea-pig and Rhesus monkey whole blood ex vivo and rabbit in vivo exhibit a thromboxane-dependent component which can be inhibited in a dose-related fashion by pretreatment with the thromboxane antagonist EP 092. In the rabbit, moreover, the data support the possibility of a role for thromboxane in the intravascular aggregatory response to thrombin.

Citing Articles

Current concepts for a drug-induced inhibition of formation and action of thromboxane A2.

Patscheke H Blut. 1990; 60(5):261-8.

PMID: 2190651 DOI: 10.1007/BF01736225.

References

Hamberg M, Samuelsson B . Prostaglandin endoperoxides. Novel transformations of arachidonic acid in human platelets. Proc Natl Acad Sci U S A. 1974; 71(9):3400-4. PMC: 433780. DOI: 10.1073/pnas.71.9.3400. View

Marin J, Sanchez-Ferrer C, Salaices M . Effects of ouabain on isolated cerebral and femoral arteries of the cat: a functional and biochemical study. Br J Pharmacol. 1988; 93(1):43-52. PMC: 1853789. DOI: 10.1111/j.1476-5381.1988.tb11403.x. View

Kinlough-Rathbone R, Packham M, Reimers H, Cazenave J, Mustard J . Mechanisms of platelet shape change, aggregation, and release induced by collagen, thrombin, or A23,187. J Lab Clin Med. 1977; 90(4):707-19. View

Addonizio Jr V, EDMUNDS Jr L, Colman R . The function of monkey (M. mulatta) platelets compared to platelets of pig, sheep, and man. J Lab Clin Med. 1978; 91(6):989-97. View

Weksler B, Ley C, Jaffe E . Stimulation of endothelial cell prostacyclin production by thrombin, trypsin, and the ionophore A 23187. J Clin Invest. 1978; 62(5):923-30. PMC: 371849. DOI: 10.1172/JCI109220. View

Morley J, Bray M, Jones R, Nugteren D, VAN DORP D . Prostaglandin and thromboxane production by human and guinea-pig macrophages and leucocytes. Prostaglandins. 1979; 17(5):729-46. DOI: 10.1016/s0090-6980(79)80044-1. View

Kennedy M, Stobo J, Goldyne M . In vitro synthesis of prostaglandins and related lipids by populations of human peripheral blood mononuclear cells. Prostaglandins. 1980; 20(1):135-45. DOI: 10.1016/0090-6980(80)90013-1. View

Vargaftig B, Chignard M, Le Couedic J, Benveniste J . One, two, three or more pathways for platelet aggregation. Acta Med Scand Suppl. 1980; 642:23-9. DOI: 10.1111/j.0954-6820.1980.tb10931.x. View

Randall M, Parry M, Hawkeswood E, Cross P, Dickinson R . UK-37, 248, a novel, selective thromboxane synthetase inhibitor with platelet anti-aggregatory and anti-thrombotic activity. Thromb Res. 1981; 23(1-2):145-62. DOI: 10.1016/0049-3848(81)90247-4. View

10.

Lewis G, Watts I . Prostaglandin endoperoxides, thromboxane A2 and adenosine diphosphate in collagen-induced aggregation of rabbit platelets. Br J Pharmacol. 1982; 75(4):623-31. PMC: 2071527. DOI: 10.1111/j.1476-5381.1982.tb09183.x. View

11.

Hornby E, SKIDMORE I . Evidence that prostaglandin endoperoxides can induce platelet aggregation in the absence of thromboxane A2 production. Biochem Pharmacol. 1982; 31(6):1158-60. DOI: 10.1016/0006-2952(82)90359-8. View

12.

Wilson N, Peesapati V, Jones R, Hamilton K . Synthesis of prostanoids with bicyclo[2.2.1]heptane, bicyclo[3.1.1]heptane, and bicyclo[2.2.2]octane ring systems. Activities of 15-hydroxy epimers on human platelets. J Med Chem. 1982; 25(5):495-500. DOI: 10.1021/jm00347a004. View

13.

Ito T, Ogawa K, Sakai K, Watanabe J, Satake T, Kayama N . Effects of a selective inhibitor of thromboxane synthetase (OKY-1581) in humans. Adv Prostaglandin Thromboxane Leukot Res. 1983; 11:245-51. View

14.

Saniabadi A, Lowe G, Forbes C, Prentice C, Barbenel J . Platelet aggregation studies in whole human blood. Thromb Res. 1983; 30(6):625-32. DOI: 10.1016/0049-3848(83)90271-2. View

15.

Gorman R, Johnson R, Spilman C, Aiken J . Inhibition of platelet thromboxane A2 synthase activity by sodium 5-(3'-pyridinylmethyl)benzofuran-2-carboxylate. Prostaglandins. 1983; 26(2):325-42. DOI: 10.1016/0090-6980(83)90099-0. View

16.

Armstrong R, Jones R, Wilson N . Ligand binding to thromboxane receptors on human platelets: correlation with biological activity. Br J Pharmacol. 1983; 79(4):953-64. PMC: 2044935. DOI: 10.1111/j.1476-5381.1983.tb10541.x. View

17.

Patscheke H, Stegmeier K . Investigation on a selective non-prostanoic thromboxane antagonist, BM 13.177, in human platelets. Thromb Res. 1984; 33(3):277-88. DOI: 10.1016/0049-3848(84)90163-4. View

18.

Banerjee A, Tuffin D, Walker J . Pharmacological effects of (+/-)-11-deoxy, 16-phenoxy-prostaglandin E1 derivatives in the cardiovascular system. Br J Pharmacol. 1985; 84(1):71-80. PMC: 1987233. View

19.

Mallarkey G, Smith G . A comparative study of the involvement of the prostaglandin H2/thromboxane A2 pathway in intravascular platelet aggregation in guinea-pigs and rats. Br J Pharmacol. 1985; 84(2):425-30. PMC: 1987276. DOI: 10.1111/j.1476-5381.1985.tb12926.x. View

20.

Armstrong R, Jones R, Peesapati V, Will S, Wilson N . Competitive antagonism at thromboxane receptors in human platelets. Br J Pharmacol. 1985; 84(3):595-607. PMC: 1987154. DOI: 10.1111/j.1476-5381.1985.tb16139.x. View